The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Items 301–400 of 958
A critical update on the l eptin‐melanocortin system
Lavoie, O., Michael, N. J., & Caron, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15765 · Cited by 46
Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 40
Buller, S., & Blouet, C. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00250.2023 · Cited by 40
Acute activation of GLP-1-expressing neurons promotes glucose homeostasis and insulin sensitivity
Shi, X., Chacko, S., Li, F., Li, D., Burrin, D., Chan, L., & Guan, X. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.08.009 · Cited by 40
Ratner, C., He, Z., Grunddal, K. V., Skov, L. J., Hartmann, B., Zhang, F., Feuchtinger, A., Bjerregaard, A., Christoffersen, C., Tschöp, M. H., et al. (2019) · Diabetes · doi:10.2337/db18-1009 · Cited by 40
Blood-to-brain communication in the hypothalamus for energy intake regulation
Takemura, S., & Wanaka, A. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.007 · Cited by 44
GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans
Hanssen, R., Kretschmer, A. C., Rigoux, L., Albus, K., Edwin Thanarajah, S., Sitnikow, T., Melzer, C., Cornely, O. A., Brüning, J. C., & Tittgemeyer, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101163 · Cited by 40
“Considering that GLP-1 application has a stronger effect on peripheral insulin secretion in insulin-resistant humans than insulin-sensitive individuals [91], it seems reasonable to assume that the central effect of GLP-1 is equally stronger in insulin-resistant humans than insulin-sensitive individuals, indicating tha…”
BackgroundKanoski, S. E., Ong, Z. Y., Fortin, S. M., Schlessinger, E. S., & Grill, H. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12423 · Cited by 40
“Further, both leptin [57] and peripherally-injected liraglutide [58] bind to proopiomelanocortin- and cocaine- and amphetamine-regulated transcript-expressing neurons in the”
BackgroundQuast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14477 · Cited by 39
“Alternative explanations are an altered expression of pancreatic enzymes in the face of insulin deficiency and/or resistance, or changed food preferences (as part of well-established reductions in appetite and caloric intake induced by GLP-1 RAs; Table 2).(4,44) However, protein intake was reduced, but faecal elastase…”
BackgroundThe vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 41
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 45
“The arcuate nucleus and nucleus of the solitary tract have been found to be involved in the regulation of appetite and food intake by liraglutide [88,96–98].”
Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
Lutz, T. A., & Osto, E. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000293 · Cited by 42
Hansen, H. H., Fabricius, K., Barkholt, P., Mikkelsen, J. D., Jelsing, J., Pyke, C., Knudsen, L. B., & Vrang, N. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.038 · Cited by 42
“Considering that liraglutide enters the rodent brain after subcutaneous dosing (Secher et al., 2014), the anorectic and body weight lowering properties of liraglutide are dependent on central GLP-1 receptor activation (Secher et al.”
BackgroundSelf-citationHornigold, D. C., Roth, E., Howard, V., Will, S., Oldham, S., Coghlan, M. P., Blouet, C., & Trevaskis, J. L. (2018) · Appetite · doi:10.1016/j.appet.2018.05.131 · Cited by 38
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“are attributed to GLP-1R expressing neurons in the hypothalamus [56] and on the vagal afferents that act via neurons in the NTS in the brain stem [57].”
BackgroundCorrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39
Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
Ludwig, M. Q., Todorov, P. V., Egerod, K. L., Olson, D. P., & Pers, T. H. (2021) · Diabetes · doi:10.2337/dbi21-0003 · Cited by 38
Falk, S., Petersen, J., Svendsen, C., Leguizamón, C. R. R., Jørgensen, S. H., Krauth, N., Ludwig, M. Q., Lundø, K., Roostalu, U., Skovbjerg, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112466 · Cited by 41
Self-citationHypothalamic inflammation and food intake regulation during chronic illness
Dwarkasing, J. T., Marks, D. L., Witkamp, R. F., & van Norren, K. (2015) · Peptides · doi:10.1016/j.peptides.2015.06.011 · Cited by 44
Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation
Vianna, A. R. D. C. B., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0059-4 · Cited by 46
“Although we did not evaluate the presence of liraglutide in the liquor, others have demonstrated that liraglutide cross through the blood-brain barrier, and has the potential to act directly on the central nervous system (Hunter and Holscher 2012; Secher et al. 2014).”
BackgroundDouton, J. E., Acharya, N. K., Stoltzfus, B., Sun, D., Grigson, P. S., & Nyland, J. E. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000685 · Cited by 36
“So far, only one study has shown fluorescently labeled liraglutide (120 nmol/kg) in the hypothalamus 4 h after a single iv injection (Secher et al., 2014).”
Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Blair, H. A., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0370-5 · Cited by 39
“This difference in bodyweight reduction may be partly due to liraglutide’s increased access to specific brain areas involved in appetite regulation [46].”
BackgroundPancreatic β‐cell imaging in humans: fiction or option?
Laurent, D., Vinet, L., Lamprianou, S., Daval, M., Filhoulaud, G., Ktorza, A., Wang, H., Sewing, S., Juretschke, H. P., Glombik, H., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12544 · Cited by 44
“A cc ep te d A rti cl e Peptides targeting the glucagon-like peptide-1 receptor (GLP-1R) are promising candidates for use in β-cell imaging because 1) they should target the β-cells with high specificity [44-55], given the”
BackgroundSelf-citationCardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 34
Gender‐related issues in the pharmacology of new anti‐obesity drugs
Cataldi, M., Muscogiuri, G., Savastano, S., Barrea, L., Guida, B., Taglialatela, M., & Colao, A. (2019) · Obesity Reviews · doi:10.1111/obr.12805 · Cited by 36
“Among them, a crucial role has been attributed to the arcuate nucleus where GLP‐1 directly stimulates anorexigenic proopiomelanocortin (POMC)/ cocaine‐ and amphetamine‐regulated transcript (CART) neurons and indirectly inhibits orexigenic neuropeptide Y (NPY) and agouti‐related peptide (AgRP) neurons.(69) In addition,…”
BackgroundKnudsen, L. B., Secher, A., Hecksher‐Sørensen, J., & Pyke, C. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12463 · Cited by 36
“Figure 2 | Distribution of liraglutide(594) or exendin(9-39)(594) in the pancreas and brain.”
BackgroundInfluentialSelf-citationMietlicki‐Baase, E. G., Liberini, C. G., Workinger, J. L., Bonaccorso, R. L., Borner, T., Reiner, D. J., Koch‐Laskowski, K., McGrath, L. E., Lhamo, R., Stein, L. M., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13222 · Cited by 36
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sandsdal, R. M., Juhl, C. R., & Torekov, S. S. (2019) · Drug Safety · doi:10.1007/s40264-019-00812-7 · Cited by 40
Interleukin-17 acts in the hypothalamus reducing food intake
Nogueira, G. A. S., Solon, C., Carraro, R. S., Engel, D. F., Ramalho, A. F. S., Sidarta-Oliveira, D., Gaspar, R. S., Bombassaro, B., Vasques, A. C. J., Geloneze, B., et al. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.12.012 · Cited by 43
Holt, M. K., Cook, D. R., Brierley, D. I., Richards, J. E., Reimann, F., Gourine, A. V., Marina, N., & Trapp, S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101024 · Cited by 35
“In fact, assuming that access to the CNS is similar for peripherally administered Ex-4 as it is for fluorescently labelled liraglutide [62,63], we would expect that Ex-4 acts in either PVN, AP/NTS or on spinal preganglionic sympathetic neurons to affect HR.”
BackgroundBakker, W., Imbernón, M., Salinas, C. G., Chao, D. H. M., Hassouna, R., Morel, C., Martin, C., Leger, C., Denis, R., Castel, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111698 · Cited by 38
Self-citationLeptin Reduction as a Required Component for Weight Loss
Zhao, S., Li, N., Xiong, W., Li, G., He, S., Zhang, Z., Zhu, Q., Jiang, N., Ikejiofor, C., Zhu, Y., et al. (2023) · Diabetes · doi:10.2337/db23-0571 · Cited by 36
Purnell, J. Q., & le Roux, C. W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15478 · Cited by 42
“For example, single and dual-hormone proteins containing a GLP-1 receptor agonist 46,47 and bupropion 48 reduce appetitive behaviours through stimulation of POMC neurons.”
BackgroundNeuroendocrine gut–brain signaling in obesity
Gruber, T., Lechner, F., Krieger, J.-P., & García‐Cáceres, C. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.05.002 · Cited by 44
Chan, Y.-C., Chuang, S., Kuo, Y., Lian, Y.-Z., & Chen, Y. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.06.083 · Cited by 44
Dalbøge, L. S., Pedersen, S. L., van Witteloostuijn, S. B., Rasmussen, J. E., Rigbolt, K. T. G., Jensen, K. J., Holst, B., Vrang, N., & Jelsing, J. (2014) · Journal of Peptide Science · doi:10.1002/psc.2727 · Cited by 36
Self-citationHindbrain GLP-1 receptor mediation of cisplatin-induced anorexia and nausea
De Jonghe, B. C., Holland, R. A., Olivos, D. R., Rupprecht, L. E., Kanoski, S. E., & Hayes, M. R. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.10.031 · Cited by 35
Skovbjerg, G., Roostalu, U., Salinas, C. G., Skytte, J. L., Perens, J., Clemmensen, C., Elster, L., Frich, C. K., Hansen, H. H., & Hecksher‐Sørensen, J. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109637 · Cited by 32
Self-citationRøder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 39
Katsurada, K., Nandi, S. S., Sharma, N. M., Zheng, H., Liu, X., & Patel, K. P. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00028.2019 · Cited by 37
Barrea, L., Pugliese, G., Muscogiuri, G., Laudisio, D., Colao, A. A. L., & Savastano, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03179-x · Cited by 38
Bae, J. H., Choi, H. J., Cho, K. I. K., Kim, L. K., Kwon, J. S., & Cho, Y. M. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0018 · Cited by 33
Guan, Z., Du, Y., Li, R., Zhang, S., Xu, Y., Zhang, X., Zhang, F., Yin, Y., Wu, K., Li, X., et al. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03249-z · Cited by 38
Ast, J., Nasteska, D., Fine, N. H. F., Nieves, D. J., Kőszegi, Z., Lanoiselée, Y., Cuozzo, F., Viloria, K., Bacon, A., Luu, N. T., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35716-1 · Cited by 36
“As expected, the GLP1RA Exendin4(1-39) (Exendin4; Ex4) was able to stimulate similar magnitude insulin secretory (Fig.”
BackgroundGlucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
“Liraglutide shares 97% similarity with GLP-1 and is characterized by its prolonged action in the body [39].”
BackgroundDesai, A., Khataniar, H., Hashash, J. G., Farraye, F. A., Regueiro, M. D., & Kochhar, G. S. (2024) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izae090 · Cited by 38
Lima, G. C., Vuolo, M. M., Batista, Â. G., Dragano, N. R. V., Solon, C., & Maróstica, M. R. (2016) · Nutrition · doi:10.1016/j.nut.2016.01.014 · Cited by 37
Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of Peptides
Sekar, R., Wang, L., & Chow, B. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00018 · Cited by 35
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
“The hypothalamus, particularly the arcuate nucleus (ARC), provides the pivotal sensing region for adiposity signals including leptin (15) and insulin (16), as well as for glucose.”
BackgroundInfluentialEffects of metabolic state on the regulation of melanocortin circuits
Lieu, L., Chau, D., Afrin, S., Dong, Y., Alhadeff, A. L., Betley, J. N., & Williams, K. W. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.113039 · Cited by 37
“While leptin, serotonin, adiponectin, and insulin directly inhibit NPY/AgRP neurons, GLP-1 indirectly inhibits NPY/AgRP neurons via GABAergic synaptic connectivity [98, 163].”
BackgroundInfluentialWagner, S., Brierley, D. I., Leeson-Payne, A., Jiang, W., Chianese, R., Lam, B. Y. H., Dowsett, G. K. C., Cristiano, C., Lyons, D., Reimann, F., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101665 · Cited by 32
“However, GLP-1R agonists show limited brain penetrance, at least acutely [2,10,11], and liraglutide-induced cFOS in neurons beyond the cir-cumventricular organs is found primarily in cells not expressing GLP-1Rs [12].”
Fortin, S. M., Chen, J. C., Petticord, M. C., Ragozzino, F. J., Peters, J. H., & Hayes, M. R. (2023) · Science Advances · doi:10.1126/sciadv.adh0980 · Cited by 32
Wang, L., Sui, L., Panigrahi, S. K., Meece, K., Xin, Y., Kim, J., Gromada, J., Doege, C. A., Wardlaw, S. L., Egli, D. M., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.12.021 · Cited by 34
“GLP-1 receptor agonists can induce weight loss in both human and rodents (de Boer et al., 2016; Nuffer and Trujillo, 2015; Secher et al., 2014).”
BackgroundElliott, J., Jackson, S., King, S., McHugh, R., Docherty, N., Reynolds, J., & le Roux, C. L. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001465 · Cited by 29
“However the current study in vagal-denervated esophagectomy patients suggests that intact vagal afferents are not required for the satiety-inducing effects of GLP-1.(37)”
BackgroundResultCardiovascular Effects of the New Weight Loss Agents
Vorsanger, M., Subramanyam, P., WEINTRAUB, H. S., Lamm, S. H., Underberg, J. A., Gianos, E., Goldberg, I. J., & Schwartzbard, A. Z. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.007 · Cited by 33
“Liraglutide also binds to GLP-1 receptors located in the arcuate nucleus of the hypothalamus, as well as mesolimbic neurons, acting on known central pathways of hunger and satiety (Central Illustration) (19,20).”
BackgroundSloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons
Kawatani, M., Yamada, Y., & Kawatani, M. (2018) · Peptides · doi:10.1016/j.peptides.2018.07.010 · Cited by 32
Nielsen, J. C. F., Hjørringgaard, C. U., Nygaard, M. M., Wester, A., Elster, L., Porsgaard, T., Mikkelsen, R. B., Rasmussen, S. A., Madsen, A. N., Schlein, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00417 · Cited by 34
Self-citationFeed Intake Regulation in Fish: Implications for Aquaculture
Soengas, J. L., Comesaña, S., Blanco, A. M., & Conde‐Sieira, M. (2024) · Reviews in Fisheries Science & Aquaculture · doi:10.1080/23308249.2024.2374259 · Cited by 36
da Silva, R. S., de Paiva, I. H. R., Mendonça, I. P., de Souza, J. R. B., Lucena‐Silva, N., & Peixoto, C. A. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01603-y · Cited by 39
“POMC neurons in the ARC are nutrient and energy responsive and express several receptors, such as the insulin receptor (INSR), Glucagon-like peptide-1 receptor (GLP-1R) and, the leptin receptor (Lepr) (Secher et al. 2014).”
Salvio, G., Ciarloni, A., Ambo, N., Bordoni, M., Perrone, M., Rossi, S., & Balercia, G. (2025) · Andrology · doi:10.1111/andr.70022 · Cited by 41
“12 As their efficacy on weight loss is established, these drugs are currently used in the pharmacological treatment of obesity, 13 and may contribute to improve testicularfunctioninsubjectssufferingfromfunctionalhypogonadism.”
Kamm, D. R., Pyles, K. D., Sharpe, M. C., Healy, L. N., Colca, J. R., & McCommis, K. S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100807 · Cited by 34
Tanaka, A., & Node, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0731-y · Cited by 32
“Interestingly, GLP-1RAs are known to reduce appetite and food intake partly via appetite-inhibitory neurotransmission signaling within the arcuate nucleus [16, 17], possibly resulting in subsequent improvements in insulin resistance and serum lipid profiles (e.”
BackgroundMechanisms Mediating the Actions of Fatty Acids in the Hypothalamus
Dragano, N. R. V., Monfort‐Pires, M., & Velloso, L. A. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.10.012 · Cited by 34
Katsurada, K., Nandi, S. S., Zheng, H., Liu, X., Sharma, N. M., & Patel, K. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01029-0 · Cited by 32
The diverse effects of brain glucagon‐like peptide 1 receptors on ingestive behaviour
Williams, D. L. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15535 · Cited by 34
“When labelled versions of these compounds are delivered peripherally, they can be observed to access circumventricular organs and some hypothalamic nuclei (Gabery et al., 2020; Secher et al., 2014).”
BackgroundWen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s312527 · Cited by 30
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 36
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 32
“GLP-1 receptors are abundantly expressed in the periventricular organs (CVO) as well as in the nuclei of the brain, which play a key role in the regulation of energy balance, including the control of food intake and energy expenditure, as well as in glucose metabolism [129,130].”
BackgroundGlucagon-like peptide-1 and insulin synergistically activate vagal afferent neurons
Iwasaki, Y., Goswami, C., & Yada, T. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.05.003 · Cited by 34
Hoang, V., Bi, J., MohanKumar, S. M. J., & Vyas, A. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126119 · Cited by 33
Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center
Ferrari, F., Fierabracci, P., Salvetti, G., Jaccheri, R., Vitti, J., Scartabelli, G., Meola, A., Magno, S., Ceccarini, G., & Santini, F. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01334-1 · Cited by 29
Romantsova, T. I. (2018) · Obesity and metabolism · doi:10.14341/omet201813-11 · Cited by 30
Martins, F. F., Santos-Reis, T., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121268 · Cited by 37
Abiola, J. O., Oluyemi, A. A., Idowu, O. T., Oyinloye, O. M., Ubah, C. S., Owolabi, O. V., Somade, O. T., Onikanni, S. A., Ajiboye, B. O., Osunsanmi, F. O., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17060736 · Cited by 40
“However, these drugs lower hemoglobin A1c, weight, and blood pressure, thereby modifying the conventional risk factors for chronic kidney disease and the progression of diabetic nephropathy [76].”
BackgroundPerez, F. A., Elfers, C., Yanovski, J. A., Shoemaker, A. H., Abuzzahab, M. J., & Roth, C. L. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14366 · Cited by 29
“GLP-1 receptors are present in the vagus nerve and widely expressed throughout the brain, including appetite-related sites in the hindbrain (nucleus of the solitary tract, area postrema) and the hypothalamus (arcuate and dorsomedial nuclei).(25) By binding to these receptors, GLP-1 modulates activity in appetite- and…”
Backgroundvan Ruiten, C. C., Veltman, D. J., Schrantee, A., van Bloemendaal, L., Barkhof, F., Kramer, M. H. H., Nieuwdorp, M., & IJzerman, R. G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac043 · Cited by 38
Kawasaki, T., Ohta, M., Kawano, Y., Masuda, T., Gotoh, K., Inomata, M., & Kitano, S. (2015) · Surgery Today · doi:10.1007/s00595-015-1135-1 · Cited by 29
“GLP-1 directly stimulates POMC/cocaine- and amphetamine-regulated transcript neurons and indirectly inhibits neurotransmissions in neurons expressing NPY via GABA-dependent signaling [11].”
BackgroundJalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“…studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
Gatta‐Cherifi, B., Mohammedi, K., Cariou, T., Poitou, C., Touraine, P. A., Raverot, G., Brue, T. C., Chanson, P., Illouz, F., Grunenwald, S., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae024 · Cited by 29
Meca, A.-D., Boboc, I. K. Ş., Mititelu-Tarțău, L., & Bogdán, M. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46060354 · Cited by 33
“These structural and stability distinctions underscore SEM’s potential advantages in bioavailability and durability, contributing to its unique profile within the landscape of insulin receptor agonists [18,58–60].”
BackgroundDong, W., Bai, J., Yuan, Q., Zhang, Y., Zhang, Y., Zhang, Z., Yang, M., Li, H., Zhao, Z., & Jiang, H. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105791 · Cited by 32
Roberts, C. A., Christiansen, P., & Halford, J. C. G. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0994-x · Cited by 30
“to act directly on POMC neurons in the arcuate nucleus of the hypothalamus [25], to suppress feeding.”
BackgroundIncretin therapy for diabetes mellitus type 2
Holst, J. J. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000516 · Cited by 32
“All rights rese food intake is dependent on this uptake [13].”
BackgroundOhbayashi, K., Oyama, Y., Yamaguchi, C., Asano, T., Yada, T., & Iwasaki, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.676869 · Cited by 30
Atanes, P., Ashik, T., & Persaud, S. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107928 · Cited by 30
Adipokines: Deciphering the cardiovascular signature of adipose tissue
Galley, J. C., Singh, S., Awata, W. M. C., Alves, J. V., & Bruder-Nascimento, T. B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115324 · Cited by 33
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 34
“The vasodilatory effect of alogliptin was reduced by endothelial denudation, NOS inhibitor LNMMA and selective guanylyl cyclase inhibitor ODQ but not exendin(9–39) (Shah et al. 2011).”
BackgroundInfluentialPleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association
Cariou, B. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30006-4 · Cited by 32
Alterations in hypothalamic gene expression following Roux-en-Y gastric bypass
Barkholt, P., Pedersen, P. J., Hay‐Schmidt, A., Jelsing, J., Hansen, H. H., & Vrang, N. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.01.006 · Cited by 29
“Recently, it was shown that peripheral administration of the GLP-1 receptor analog, liraglutide, gains access to the hypothalamus with the body weight lowering effects being, at least partly, dependent on increased CART expression in the Arc [49].”
BackgroundSelf-citationGLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice
Décarie-Spain, L., Fisette, A., Zhu, Z., Yang, B., DiMarchi, R. D., Tschöp, M. H., Finan, B., Fulton, S., & Clemmensen, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.035 · Cited by 27
“cribed to receptor populations expressed in the hypothalamus and hindbrain (Hayes et al., 2011; Secher et al., 2014; Turton et al., 1996).”
Wean, J., Kowalsky, A. H., Laker, R., Will, S., Drucker, D. J., Rhodes, C. J., & Seeley, R. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102074 · Cited by 28
“The body weight loss caused by both GLP-1R and GIPR agonism is mediated through the brain [16,23 e 25].”
Arcuate Nucleus of the Hypothalamus: Anatomy, Physiology, and Diseases
Song, J., & Choi, S. (2023) · Experimental Neurobiology · doi:10.5607/en23040 · Cited by 40
“Glucagon-like peptide-1 (GLP-1) binds to the GLP-1 receptor in ARH POMC+ neurons, thus suppressing food intake [110-112].”
BackgroundCurrent Long-Term Pharmacotherapies for the Management of Obesity
Kim, B.-Y., Kang, S. M., Kang, J., Kim, K. K., Kim, B., Kim, S. J., Kim, Y., Kim, J. H., Kim, J. H., Nam, G. E., et al. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20010 · Cited by 29
Exendin-4 reduces food intake via the PI3K/AKT signaling pathway in the hypothalamus
Yang, Y., Choi, P. P., Smith, W. W., Xu, W., Ma, D., Cordner, Z. A., Liang, N., & Moran, T. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-06951-0 · Cited by 32
Usui, R., Yabe, D., Kuwata, H., Murotani, K., Kurose, T., & Seino, Y. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.020 · Cited by 28
Binding sites and design strategies for small molecule GLP-1R agonists
Zhang, H., Wu, T., Wu, Y., Peng, Y., Wei, X. H., Lu, T., & Jiao, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116632 · Cited by 29
Chakravartti, S. P., Jann, K., Veit, R., Liu, H., Yunker, A. G., ANGELO, B. C., Monterosso, J. R., Xiang, A. H., Kullmann, S., & Page, K. A. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01227-8 · Cited by 29
“Studies in rodent models have shown that GLP-1 influences hypothalamic and brainstem pathways involved in appetite regulation and glucose sensing 49,50 .”
Kuhre, R. E., Ballarín-González, B., Brand, C. L., Glendorf, T., Madsen, K. G., Hjøllund, K. R., Hogendorf, W. F. J., Ipsen, D. H., Lundh, S. H., Kruse, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105862 · Cited by 29
“…we employed a GLP-1RA sequence connected at the C-terminus by a short peptide spacer to a 32-amino acid disulphide-free calcitonin-based amylin sequence, with an albumin-binding C18 diacid-based sidechain added at position 37, which is expected to provide broad protection against metabolism.”
Self-citationTargeting the gastrointestinal tract to treat type 2 diabetes
Bauer, P. V., & Duca, F. A. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0056 · Cited by 29
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.